Form 4: Merus COO Sells Options in Genmab Tender Offer

Sentiment:

Beneficial Ownership Change 12 December 2025 7:02 PM

Merus N.V.'s COO and GC, Peter B. Silverman, disposed of all his share options for cash as part of Genmab's tender offer for Merus shares at $97.00 per share.

Summary

Merus N.V. entered into a transaction agreement with Genmab A/S and its wholly owned subsidiary, Genmab Holding II B.V., on September 29, 2025.
Pursuant to this agreement, Genmab Holding II B.V. commenced a tender offer for all issued and outstanding common shares of Merus N.V.
On December 12, 2025, the Purchaser accepted all shares that were validly tendered and not properly withdrawn, in exchange for a cash payment of $97.00 per share, without interest and less applicable withholding taxes.
Peter B. Silverman, Merus N.V.'s COO & GC, disposed of all his share options on December 12, 2025.
These options were cancelled in exchange for a cash payment equal to the product of (i) the amount by which the Offer Consideration ($97.00) exceeds the applicable exercise price per share of such option and (ii) the aggregate number of shares underlying such option.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a tender offer and the monetization of executive stock options, indicating a positive outcome for the reporting person and the company's shareholders through the acquisition. The transaction provides liquidity and a premium for shares.

Positives

The reporting person, Peter B. Silverman, realized significant cash value from the cancellation of his share options due to the tender offer.
The tender offer at $97.00 per share provides a clear and attractive exit for Merus N.V. shareholders, offering liquidity and a premium.
The transaction ensures that executive equity incentives are monetized in alignment with the value delivered to shareholders through the acquisition.

Negatives

The reporting person no longer holds any derivative securities in Merus N.V. following the transaction.
Merus N.V. will cease to be an independent publicly traded company upon completion of the acquisition by Genmab.

Future Outlook

The filing primarily reports a completed transaction. It implies the future ownership of Merus N.V. by Genmab, but no specific forward-looking statements regarding Merus's operational or financial performance post-acquisition are provided.

Industry Context

This transaction represents a strategic acquisition within the biotechnology sector, where larger pharmaceutical or biotech companies like Genmab acquire innovative firms such as Merus N.V. to expand their product pipelines, intellectual property, and market reach. Such consolidations are a common trend, driven by the need for growth, diversification, and access to novel therapeutic platforms.

Comparison to Industry Standards

The tender offer price of $97.00 per share likely includes a significant premium over Merus N.V.'s pre-announcement trading price, which is a standard practice in M&A to ensure shareholder approval and successful acquisition.
The method of compensating executives for their stock options by paying the difference between the offer price and the exercise price is a widely accepted and standard practice in corporate acquisitions, aligning executive interests with shareholder value realization.
This acquisition aligns with broader industry trends seen in other significant biotech deals, such as Pfizer's acquisition of Seagen or AbbVie's acquisition of ImmunoGen, where companies with promising oncology assets are targeted for their strategic value.

Stakeholder Impact

Shareholders: Received $97.00 per share in cash, providing immediate liquidity and a premium for their investment.
Employees: Future employment status, roles, and benefits will be subject to Genmab's integration plans post-acquisition.
Executives: Peter B. Silverman, as COO & GC, monetized his equity incentives, aligning his financial interests with the acquisition's success.

Next Steps

Payment of the Offer Consideration to shareholders as soon as practicable following the Acceptance Time.
Integration of Merus N.V.'s operations and assets into Genmab A/S.

Key Dates

Date	Description
2025-09-29	Merus N.V. entered into a transaction agreement with Genmab A/S and Genmab Holding II B.V.
2025-12-12	Purchaser accepted all validly tendered shares in the tender offer (Acceptance Time).
2025-12-12	Peter B. Silverman's share options were cancelled and disposed of for cash.
2029-02-20	Expiration date of 3,900 share options with an exercise price of $11.16.
2030-04-16	Expiration date of 12,714 share options with an exercise price of $12.37.
2031-02-16	Expiration date of 50,000 share options with an exercise price of $24.43.
2032-01-31	Expiration date of 83,000 share options with an exercise price of $24.61.
2033-01-01	Expiration date of 20,000 share options with an exercise price of $15.87.
2033-02-02	Expiration date of 104,000 share options with an exercise price of $16.07.
2034-01-31	Expiration date of 107,300 share options with an exercise price of $36.09.
2035-01-29	Expiration date of 125,000 share options with an exercise price of $41.65.

Recommendation

sell

The company, Merus N.V., is being acquired by Genmab A/S through a tender offer at $97.00 per share. For current shareholders, the recommendation is to tender their shares to realize the cash value. For potential investors, there is no longer an independent investment thesis for Merus N.V. as it will cease to be a publicly traded entity.

Keywords

Merus N.V., MRUS, Genmab A/S, Tender Offer, Share Options, Beneficial Ownership, SEC Form 4, Acquisition, Peter B. Silverman, COO, GC

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.